NCT00001277 - Studies of Elevated Parathyroid Activity | Biotech Hunter

Enrollment

1,553

Participants

Timeline

Start Date

December 15, 1993

Primary Completion Date

March 11, 2020

Study Completion Date

December 23, 2020

Conditions

HyperparathyroidismHypercalcemiaParathyroid NeoplasmMultiple Endocrine NeoplasiaMEN1

Interventions

DRUG

68Ga-Dotatate

68Ga-Dotatate PET/CT will be administered prior to a PET/CT scan to detect known and occult primary and metastatic bronchial, gastrointestinal and pancreatic neuroendocrine tumors.

DRUG

18F-DOPA

18F-DOPA PET/CT will be administered prior to a whole-body scan to detect known and occult primary and metastatic bronchial, gastrointestinal and pancreatic neuroendocrine tumors.

Trial Locations (1)

20892

National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda

All Listed Sponsors

lead

National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

NIH